Abstract
This pilot study involved six men with major depression treated with nefazodone dosed either twice/day or once/day at bedtime. Depression was rated before nefazodone therapy and at 4 weeks by the self-report version of the Hamilton Depression Rating Scale. A simple 10-cm visual analog side effect scale for daytime drowsiness was completed at the latter time. Dosages of nefazodone were at least 400 mg/day. The results suggest that nefazodone given once/day at bedtime may be as effective as the currently accepted twice/day regimen, with less daytime drowsiness.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Adult
-
Aged
-
Antidepressive Agents, Second-Generation / administration & dosage*
-
Antidepressive Agents, Second-Generation / therapeutic use
-
Depression / drug therapy
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Humans
-
Male
-
Middle Aged
-
Piperazines
-
Self-Assessment
-
Severity of Illness Index
-
Time Factors
-
Triazoles / administration & dosage*
-
Triazoles / therapeutic use
Substances
-
Antidepressive Agents, Second-Generation
-
Piperazines
-
Triazoles
-
nefazodone